주요우울증에서 치료반응을 예측할 수 있는가?

키워드

참고문헌 (96)

1. Horwath E, "Epidemiology of depressionand anxiety disorders in Textbook in PsychiatricEpidemology Edited by Tsung MT" (1995)
2. Lee JK, "Korean epidemiologic research of mental disorder", pp.1223~1244
3. Sackeim HA, "The definition and meaning of treatmentresistantdepression", 62, pp.10~17 (2001)
4. Roose SP, "Comparativeefficacy of selective serotonin reuptake inhibitorsand tricyclics in the treatment of melancholia", pp.1735~1739
5. Anderson IM, "SSRIS versus tricyclic antidepressants indepressed inpatients: a meta-analysis of efficacy and tolerability", 7, pp.11~17 (1998)
6. Rosen RC, "Effects of SSRIs onsexual function: a critical review", 19, pp.67~85 (1999)
7. Jones D, "Monoamine metabolitesas predictors of antidepressant response", pp.229~240
8. Ebert MH, "Effect of physicalactivity on urinary M excretion in depressed patients"
9. Hollister LE, "Asthma and alcohol withdrawal as sources of artefact inurinary excretion of 3-methoxy-4-hydroxyl phenylglycol", k(pes k), pp.135~140
10. Beckmann H, "Urinary MHPG in subgroupsof depressed patients and normal controls", pp.91~100
11. Beckmann H, "Antidepressant responseto tricyclics and urinary MHPG in unipolar patients Clinical response to imipramine or amitriptyline", pp.17~21
12. Fawcett J, "Response to dextroamphetamine and tricyclic antidepressants", pp.246~251, Depression and MHPG excretion
13. Hollister LE, "Subtypes of depressionbased on excretion of MHPG and response tonortriptyline", pp.1107~1110
14. Rosenbaum AH, "MHPG as a predictor ofantidepressant response to imipramine and maprotiline", pp.1090~1092
15. Coppen A, "Urinary 4-hydroxy-3-methoxyphenylglycolis not a predictor for clinical response to amitriptyline indepressive illness", pp.95~97 (1979)
16. Edwards D, "Urinary MHPG and clinical response to amitriptyline indepressed patients", pp.1183~1187
17. Gaertner HJ, "Do urinary MHPG and plasma drug levelscorrelate with response to amitriptyline therapy? Psychopharmacology", pp.236~239 (1982)
18. Esler M, "The peripheral kinetics of norepinephrinein depressive illness", pp.295~300
19. Kelly CB, "Plasma noradrenaline responseto electroconvulsive therapy in depressive illness", 171, pp.182~186 (1997)
20. Wyatt RJ, "Resting plasma catecholamine concentrations inpatients with depression and anxiety", pp.65~70
21. Roy A, "Plasma norepinephrinelevel in affective disorders", lin(ila m), pp.1181~1185
22. Werstiuk ES, "Effects of electroconvulsive therapy on peripheraladrenoceptors, plasma, noradrenaline, MHPG and cortisolin depressed patients", 169, pp.758~765 (1996)
23. Cooper SJ, "Effects of electroconvulsive therapy", pp.23~29, Adrenergic receptorsin depression
24. Johnston TG, "Plasma norepinephrine and prediction of outcome in majordepressive disorder", 46, pp.1253~1258 (1999)
25. Van Kempen GM, "Repeatedmeasures of platelet MAO activity and 5-HT in a groupof suicidal women", (tten p), pp.529~530
26. Mann JJ, "Platelet and whole blood serotonin content in depressedinpatients correlations with acute and life-timepsychopathology", pp.243~257
27. Widmer J, "Plateletserotonin and plasma tryptophan in depressed patients effect of drug treatment and clinical outcome", pp.207~214
28. Goodnick PJ, "Neurochemistry andparoxetine response in major depression", 37, pp.417~419 (1995)
29. Lestra C, "Biologicalparameters in major depression: effects of paroxetine,viloxazine, moclobemide, and electroconvulsive therapy.Relation to early clinical outcome.", 44, pp.274~280 (1998)
30. Celada P, "Effects ofacute and chronic treatment with fluvoxamine on extracellularand platelet serotonin in the blood of majordepressive patients.", pp.243~249
31. Thoren P, "5-HIAA in the cerebrospinalfluid", pp.1193~1197
32. Nuutila A, "Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiatesimpulsive from nonimpulsive violent behavior", lin(ila m), pp.2609~2614
33. Van Praag HM, "New evidence of serotonin-deficientdepressions", pp.56~63
34. "Correlation of anxiety and related symptomswith cerebrospinal fluid 5-hydroxyindoleacetic acid indepressed women", pp.135~143
35. Tuck D, "Indoleamine metabolites in the cerebrospinalfluid of depressed patients before and during treatmentwith nortriptyline", pp.277~286
36. Post RM, "Effects of a dopamineagonist piribedil in depressed patients relationship ofpretreatment homovanillic acid to antidepressant response", pp.609~615
37. Van Scheyen JD, "Controlledstudy comparing nomifensine and clomipramine in unipolardepression"
38. Moller SE, "Relationship betweenplasma ratio of tryptophan to competing amino acidsand the response to L-tryptophan treatment in endogenouslydepressed patients", pp.47~59
39. Moller SE, "Tryptophan and tyrosineratios to neutral amino acids in endogenousdepression Relation to antidepressant response to amitriptylineand lithium+L-tryptophan", pp.67~79
40. Moller SE, "Plasma tryptophanand tyrosine ratios to competing amino acids inrelation to antidepressant response to citalopram andmaprotiline", pp.96~100 (1986)
41. Giller E Jr, "Assessingtreatment response to the monoamine oxidaseinhibitor isocarboxazid", pp.44~48
42. Georgotas A, "Prediction of response to nortriptyline and phenelzine byplatelet MAO activity", pp.338~340
43. "Clinical and biological parameters as predictorsfor antidepressant drug responses in depressedpatients", pp.179~185
44. Davidson RT, "Redblood cell catechol O-methyl transferase and response toimipramine in unipolar depressive women", pp.952~955
45. Arana GW, "The dexamethasonesuppression test for diagnosis and prognosisin psychiatry", pp.1193~1204
46. Gardner R, "Dexamethasone suppression testsin antidepressant treatment of melancholia", pp.493~500
47. Liebl R, "Repeated dexamethasonesuppression test during depressive illness Normalisation of test result compared with clinicalimprovement", pp.93~101
48. "a marker for early relapse", pp.305~318, Persistent neuroendocrine dysregulation inmajor depressive disorder
49. Brown WA, "Response to dexamethasone andsubtype of depression", pp.747~751
50. Peselow ED, "Dexamethasonesuppression test in predicting response totricyclic antidepressants in depressed outpatients", pp.206~211
51. Gitlin MJ, "The dexamethasone suppressiontest and response to somatic treatment", pp.16~21
52. Fraser AR, "Choice of antidepressant based on the dexamethasonesuppression test", pp.786~787
53. Brown WA, "marker of a subtype with characteristicclinical features and response to treatment? PsychiatryRes 1981;4", pp.115~128, Pituitary-adrenal disinhibitionin depression
54. Georgotas A, "The usefulness of DSTin predicting response to antidepressants", pp.21~28
55. Rush AJ, "Cognitive therapy of depression", pp.105~127
56. Zobel AW, "Cortisol response in the combined dexamethasone", CRH test as predictor of relapse in patients withremitted depression, 2001, pp.35, 83~94
57. "The thyrotropin response to thyrotropinreleasinghormone in endogenous depression", Kirkegaard C
58. Extein I, "Does subclinical hypothyroidismpredispose to tricyclic-induced rapid moodcycles? J Clin Psychiatry 1982;43", pp.290~291
59. Baulieu EE, "Dehydroepiandrosterone(DHEA)and dehydroepiandrosterone sulfate(DHEAS) as neuroactiveneurosteroids.", 95, pp.4089~4091 (1998)
60. Maayan R, "Basal plasma dehydroepiandrosteronesulfate level: a possible predictor for response toelectroconvulsive therapy in depressed psychotic inpatients", 48, pp.693~701 (2000)
61. Lesch KP, "Association of anxiety-related traitswith a polymorphism in the serotonin transporter generegulatory region", 274, pp.1527~1531 (1996)
62. Hoehe MR, "Serotonin transporter(5-HTT) gene polymorphisms are not associatedwith sus-ceptibility to mood disorders.", 81, pp.1~3 (1998)
63. Rees M, "Association studies of bipolardisorder at the human serotonin transporter gene(hSERT;5HTT).", 2, pp.398~402 (1997)
64. Smeraldi E, "Polymorphism within the promoterof the serotonin transporter gene and antidepressant efficacyof fluvoxamine", 3, pp.508~511 (1998)
65. Zanardi R, "Efficacy of paroxetine in depression isinfluenced by a functional polymorphism within thepromoter of the serotonin transporter gene", 20, pp.105~107 (2000)
66. Serretti A, "Influence of tryptophan hydroxylase andserotonin transporter genes on fluvoxamine antidepressantactivity", 6, pp.586~592 (2001)
67. Zanardi R, "Factors affecting fluvoxamineantidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression", 50, pp.323~330 (2001)
68. Pollock BG, "Allelic variation in the serotonintransporter promoter affects onset of paroxetinetreatment response in late-life depression", 23, pp.587~590 (2000)
69. Arias B, "5-HTTLPR polymorphism of the serotonin transportergene predicts non-remission in major depression patientstreated with citalopram in a 12-weeks follow up study", 23, pp.563~567 (2003)
70. Kim DK, "Serotonin transporter gene polymorphismand antidepressant response", 11, pp.215~219 (2000)
71. Yoshida K, "Influence of the serotonin transportergene-linked polymorphic region on the antidepressantresponse to fluvoxamine in Japanese depressed patients", 26, pp.383~386 (2002)
72. Lee HY, "5-HTTLPR and LongtermEffect of Antidepresant Treatment in Korean DepressivePatients", 9, pp.34~41 (2002)
73. Smeraldi E, "Serotonin transporterpromoter genotype and illness recurrence in mooddisorders", 12, pp.73~75 (2002)
74. Ball D, "The serotonin transporter gene^peerratedneuroticism", 8, pp.1301~1304 (1997)
75. Heils A, "Allelic variation of human serotonintransporter gene expression", 66, pp.2621~2624 (1996)
76. Collier DA, "The serotonin transporter is a potentialsusceptibility factor for bipolar affective disorder", 7, pp.1675~1679 (1996)
77. Ohara K, "Functional polymorphism in the serotonintransporter promoter at the SLC6A4 locus and mooddisorders", 44, pp.550~554 (1998)
78. Benedetti F, "Influence of a functionalpolymorphism within the promoter of the serotonin transportergene on the effects of total sleep deprivation inbipolar depression", 156, pp.1450~1452 (1999)
79. Mundo E, "The role of serotonin transporter protein gene inantidepressant-induced mania in bipolar disorder: preliminaryfindings", 58, pp.539~544 (2001)
80. Serretti A, "Tryptophan hydroxylase gene associatedwith paroxetine antidepressant activity", pp.375~380 (2001)
81. Cusin C, "Influence of monoamine oxidase Aand serotonin receptor 2A polymorphisms in SSRI antidepressantactivity", 5, pp.27~35 (2002)
82. Minov C, "Serotonin-2A-receptor and -transporterpolymorphisms: lack of association in patients withmajor depression", 303, pp.119~122 (2001)
83. Baghai TC, "Possible influence of theinsertion", deletion polymorphism in the angiotensin Iconvertingenzyme gene on therapeutic outcome inaffective disorders, 2001, pp.6, 258~259
84. Hong CJ, "Association study ofangiotensin I-converting enzyme polymorphism andsymptomatology and antidepressant response in majordepressive disorders", 109, pp.1209~1214 (2002)
85. Serretti A, "No association between dopamine D(2) and D(4) receptor gene variants and antidepressantactivity of two selective serotonin reuptake inhibitors", 104, pp.195~203 (2001)
86. Serretti A, "Dopamine receptor D4 is not associatedwith antidepressant activity of sleep deprivation", 89, pp.107~114 (1999)
87. Schumann G, "Antidepressiveresponse to sleep deprivation in unipolar depression isnot associated with dopamine D3 receptor genotype", 43, pp.127~130 (2001)
88. Zill P, "Evidence for an association between aG-protein beta3-gene variant with depression and responseto antidepressant treatment", 11, pp.1893~1897 (2000)
89. Serretti A, "SSRIs antidepressant activity isinfluenced by G beta 3 variants", 13, pp.117~122 (2003)
90. Lee HJ, "Association between a G-protein beta 3 subunitgene polymorphism and the symptomatology andtreatment responses of major depressive disorders", 4, pp.29~39 (2004)
91. Coble PA, "EEG sleep in primary depression", pp.131~138
92. Svendsen K, "Duration of REM sleeplatency as predictor of effect of antidepressant therapy", pp.238~243
93. Riemann D, "InitialREM sleep suppression by clomipramine a prognostictool for treatment response in patients with a majordepressive disorder EEG sleep changes as predictors in depression Anterior cingulateactivity as a predictor of degree of treatment responsein major depression evidence from brain electrical tomographyanalysis a potential predictor of treatment response Prediction of antidepressant effectsof sleep deprivation by metabolic rates in the ventralanterior cingulate and medial prefrontal cortex Pretreatment orthostatic hypotension as a predictor ofresponse to nortriptyline in geriatric depression Pretreatmentorthostatic hypotension in geriatric depression predictor of response to imipramine and doxepin Distal colon motility as a predictor ofantidepressant response to fenfluramine Behavioral predictors of amitriptylineresponse in depression", pp.1217 212 622 405 1057 1149 172 368 27 345 30~1220 220 626 415103 1061 1158 176 372 35 352 34, Depression Cingulate function indepression Facial EMG activity levels predict treatment outcomein depression
94. Pizzagalli D, "Anterior cingulateactivity as a predictor of degree of treatment responsein major depression: evidence from brain electrical tomographyanalysis.", 158, pp.405~415 (2001)
95. Mayberg HS, "Cingulate function indepression: a potential predictor of treatment response", 8, pp.1057~1061 (1997)
96. Wu J, "Prediction of antidepressant effectsof sleep deprivation by metabolic rates in the ventralanterior cingulate and medial prefrontal cortex.", 156, pp.1149~1158 (1999)

관련 논문AI추천